After Purdue, Larry worked for Eli Lilly and Company in Indianapolis ... Larry will be missed by family and many friends and acquaintances. After cremation, Larry will be buried along with ...

Last week, Ecolumber, a Spanish firm dedicated to of walnut trees in ... US laboratory Eli Lilly, which has been taken over by the local Laboratorios Raffo, and the Chinese oil company Sinopec ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

I'm Chris Schott at JPMorgan and it's my pleasure to be hosting this fireside chat today with Dave Ricks, Chairman and CEO of Eli Lilly. It's been a tremendous few years for the Company.

Investing.com -- Eli Lilly and Company (NYSE:LLY) has projected its full-year global revenue for 2024 to reach around $45 billion, marking a 32% increase from the prior year. The company also ...

Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and delivering life-changing medicines to address some of the world's most pressin ...

Eli Lilly announced preliminary fourth-quarter revenue of roughly $13.5 billion, or $400 million below the low end of its guidance, driven by slower-than-expected US market growth and lower ...

2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, which represents growth of 32% compared ...

Shares of Eli Lilly (NYSE:LLY) are down 7.6% today, reflecting market disappointment in the company's adjusted guidance for the fourth quarter of 2024. The pharmaceutical giant expects only $13.5 ...

The company forecasts 2025 sales of $58 billion to $61 billion. So taken as a whole, is this news bad enough to justify selling Eli Lilly stock -- and all the other GLP-1 stocks, too -- today?